CytRx Corporation has initiated a pharmacokinetic clinical trial designed to evaluate its oncology drug candidate bafetinib in patients with recurrent brain tumours.
The trial will evaluate patients with primary brain cancer or recurrent brain metastases who have undergone brain surgery at the City of Hope Cancer Center in the US.
The primary objective of the study will be to obtain neuropharmacokinetic information, such as the ability of bafetinib to cross the blood-brain barrier.
The trial results are expected in the second quarter of 2011. The company plans to use these results to further develop bafetinib for the treatment of brain cancer.